Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07075198 · ClinicalTrials.gov registry record · NA

Caesar Foot Take-Home Validation Testing

A NA study of Prosthesis User and Lower Limb Amputation Below Knee (Injury), sponsored by Liberating Technologies.

Recruiting
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT07075198: Recruiting NA study of Prosthesis User and Lower Limb Amputation Below Knee (Injury), sponsored by Liberating Technologies.

NCT07075198 is a NA study of Prosthesis User and Lower Limb Amputation Below Knee (Injury) that is actively recruiting participants, run by Liberating Technologies. The registered enrollment target is 18 participants, below the 56-participant average among 12 other Prosthesis User trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07075198, a NA study of Prosthesis User and Lower Limb Amputation Below Knee (Injury), is actively recruiting participants, sponsored by Liberating Technologies.

RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The rationale for this study is to conduct a take-home clinical trial to evaluate the impact of the bimodal Caesar foot in a real-world environment. Participants will take the device home and use it throughout their daily life for two months. A one-month baseline period, using their usual foot, will be completed both before and after the two-month period with the Caesar foot condition. Self-report surveys and performance-based measures will be collected in the clinic at the end of each condition. The intent of this study is to determine the Caesar foot's feasibility in a real-world environment. Data will be collected to understand impact to the user's daily life and physical activity through outcomes and participant feedback. The feedback obtained during this study will be essential to informing the design intended for commercialization.

Primary Outcome

The version of the PLUS-M being administered consists of 22 questions. Each question asks about their ability to ambulate in certain instances and at certain speeds, and is scored on a scale of 1 (unable to do) to 5 (without any difficulty). A higher score indicates a better outcome. This survey will be given at the end of each study condition. Since the first month of the Caesar condition will be for training and acclimation, the PLUS-M will be given after the second month that the participant

Interventions

  • DEVICE Caesar Foot

Study Locations (1)

Texas

  • Hanger Clinic - Austin

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2025-10
Est. Completion 2026-08
Phase NA
Liberating Technologies

13 total trials

What NCT07075198 shows while recruiting

NCT07075198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 56-participant average among 12 other Prosthesis User trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Prosthesis User appearing as the primary indexed condition, and to 1 intervention - of which Caesar Foot is the first listed.

NCT07075198 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07075198 about?

NCT07075198 is a clinical study titled "Caesar Foot Take-Home Validation Testing". The rationale for this study is to conduct a take-home clinical trial to evaluate the impact of the bimodal Caesar foot in a real-world environment. Participants will take the device home and use it throughout their daily life for two months. A one-month baseline period, using their usual foot, will...

What is the current status of trial NCT07075198?

This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2025-10. Estimated completion is 2026-08.

What conditions does trial NCT07075198 study?

This clinical trial studies the following conditions: Prosthesis User, Lower Limb Amputation Below Knee (Injury).

What interventions are being tested in trial NCT07075198?

The interventions under investigation include: Caesar Foot (DEVICE).

Who is sponsoring clinical trial NCT07075198?

This trial is sponsored by Liberating Technologies, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07075198 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prosthesis User

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07075198's enrollment target sits among peer trials

18 8th of 12 higher than 5 of 12 other Prosthesis User trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prosthesis User trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07075198, the US trial registry maintained by the National Library of Medicine. NCT07075198 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.